This filer is no longer a domestic reporting company, so the score does not apply to it now. Its history is below.
Hover or tap a dot to see the filings behind that score.
Transphorm, Inc. (the “Company”) is not, without unreasonable effort and expense, able to file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 (the “Form 10-Q”) within the prescribed time period due to the circumstances described below. In connection with the Company’s preparation of its financial statements as of and for the fiscal quarter ended December 31, 2023, the Company identified internal control deficiencies that may have resulted in errors to previously filed financial statements and which have created the need to conduct additional review and testing relating to: (i) the Company’s revenue recognition processes over accounting for variable consideration in the form of provision of free products to certain customers and timing of revenue recognition at period end in accordance with the terms and conditions included in customer contracts; and (ii) the Company’s cash flow statement, primarily related to the effect that foreign exchange rates had on cash held by the Company’s foreign subsidiaries. The Company has previously identified and disclosed a material weakness in internal control over financial reporting resulting from inadequate staff members with technical accounting knowledge and financial reporting experience which has caused the error identified in subsection (ii) above. As of the date hereof, the Company has not identified any material errors in previously filed financial statements; however, the Company has not yet completed its review procedures and the assessment of the severity of the internal control deficiencies. The Company expects to file the Form 10-Q within the extension period provided by Rule 12b-25
NT 10-Q, filed 2024-02-15 · material weakness
Transphorm, Inc. (the “Company”) is not, without unreasonable effort and expense, able to file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 (the “Form 10-Q”) within the prescribed time period due to the circumstances described below. In connection with the Company’s preparation of its financial statements as of and for the fiscal quarter ended December 31, 2023, the Company identified internal control deficiencies that may have resulted in errors to previously filed financial statements and which have created the need to conduct additional review and testing relating to: (i) the Company’s revenue recognition processes over accounting for variable consideration in the form of provision of free products to certain customers and timing of revenue recognition at period end in accordance with the terms and conditions included in customer contracts; and (ii) the Company’s cash flow statement, primarily related to the effect that foreign exchange rates had on cash held by the Company’s foreign subsidiaries. The Company has previously identified and disclosed a material weakness in internal control over financial reporting resulting from inadequate staff members with technical accounting knowledge and financial reporting experience which has caused the error identified in subsection (ii) above. As of the date hereof, the Company has not identified any material errors in previously filed financial statements; however, the Company has not yet completed its review procedures and the assessment of the severity of the internal control deficiencies. The Company expects to file the Form 10-Q within the extension period provided by Rule 12b-25
2023-07-06auditor changed or resigned SEC →
Transphorm, Inc. (the “Company”) is not, without unreasonable effort and expense, able to file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2022 (the “Form 10-Q”) within the prescribed time period due to a delay in completion of the financial statements for the quarter ended December 31, 2022. The delay in the issuance of the Company’s financial statements is attributable to the Company reevaluating the Company’s treatment of an epiwafer WIP sub-assembly inventory-related adjustment. Resolving this matter requires investigation of the supporting documentation and additional work and analysis. The Company expects to file the Form 10-Q within the extension period provided by Rule 12b-25
reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.
Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.
See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.Every item above is a filing this company
made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not
investment advice